Lantern Pharma spins out Open Medicine AI, reports deepening LP-300 survival signal
Lantern's Q2 2026 update covers a new AI subsidiary, an EGFR L858R lung cancer data update, an EMA-cleared bladder cancer trial, and $7.4 million in cash.
Lantern Pharma reported second quarter 2026 results on August 14, 2026, alongside several pipeline and corporate updates. In August, Lantern established Open Medicine AI as a separate company and entered into board-approved commercial licensing agreements.1 OMAI is currently 100% owned by Lantern Pharma, and it intends to obtain additional funding in exchange for equity in OMAI, with the longer-term objective of becoming a newly listed company on a national stock exchange or market, while Lantern expects to remain one of OMAI's largest shareholders.1 Development is anchored by AI Centers of Excellence in Dallas, Texas and Bengaluru, India, and in July 2026 the company launched ZetaOmics, the computational-biology module of the platform.1 A dedicated OMAI call is planned for mid-September 2026.
On the clinical side, median progression-free survival reached 8.9 months among EGFR exon 21 L858R patients who completed six cycles of LP-300 (n=9), compared with 8.4 months across the overall L858R cohort (n=16), with a hazard ratio of 0.37 (95% CI 0.15–0.89) for that subgroup.1 Following a May 2026 Type C meeting at which the FDA raised no objections, the company implemented protocol changes concentrating enrollment on L858R patients, extending maximum treatment cycles from six to eight, and moving to a single-arm design.1
In July 2026, the EMA cleared an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in advanced, recurrent bladder cancer, designed to enroll up to approximately 39 patients using a dual biomarker selection strategy combining PTGR1 overexpression with tumor DNA-damage repair deficiency.1 Separately, Lantern is preparing an FDA-cleared Phase 1b/2 trial of LP-184 monotherapy in relapsed or refractory TNBC, designed to enroll approximately 40 patients.1
On finances, cash, cash equivalents, and marketable securities were approximately $7.4 million as of June 30, 2026, compared to approximately $10.1 million as of December 31, 2025.1 The quarter's funding included about $4.4 million in gross proceeds from a registered direct offering closed May 14, 2026, and the company intends to pursue additional capital raises and collaborations to extend its runway.1 Loss from operations was approximately $3.5 million, down from $4.7 million a year earlier, a decrease of about 25%.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.